Exploring Three SEHK Growth Companies With Strong Insider Ownership

In This Article:

As global markets navigate through mixed economic signals and shifting investor sentiment, the Hong Kong market has shown resilience, with the Hang Seng Index recently experiencing a notable rise. In this context, exploring growth companies in Hong Kong with high insider ownership can offer valuable insights into firms that potentially have aligned interests between management and shareholders, fostering robust corporate governance which is crucial during uncertain market conditions.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

20.1%

104.1%

New Horizon Health (SEHK:6606)

16.6%

62.3%

Fenbi (SEHK:2469)

32.2%

43%

DPC Dash (SEHK:1405)

38.2%

89.7%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.5%

79.3%

Adicon Holdings (SEHK:9860)

22.3%

29.6%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Zhejiang Leapmotor Technology (SEHK:9863)

15%

73.8%

Beijing Airdoc Technology (SEHK:2251)

27.8%

83.9%

Click here to see the full list of 53 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Alibaba Health Information Technology

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Alibaba Health Information Technology Limited operates in Mainland China and Hong Kong, focusing on pharmaceutical direct sales, e-commerce platforms, and healthcare digital services with a market cap of approximately HK$62.07 billion.

Operations: The company generates revenue primarily through its distribution and development of pharmaceutical and healthcare business, totaling CN¥27.03 billion.

Insider Ownership: 24.2%

Earnings Growth Forecast: 23.1% p.a.

Alibaba Health Information Technology, a growth-oriented company in Hong Kong, reported a significant increase in net income and sales for the fiscal year ending March 2024, with net income rising to CNY 883.48 million from CNY 535.65 million the previous year. Despite substantial earnings growth of 65.6% last year and a forecasted annual earnings increase of 23.1%, concerns include shareholder dilution and below-market forecast return on equity at just 13.5%. The company's revenue is expected to grow at 11.2% annually, outpacing the Hong Kong market's average but falling short of high-growth benchmarks.